24 completed, 7 recruiting, 5 terminated, 3 withdrawn. 19 Phase 3, 9 Phase 2, 7 Phase 4, 4 Phase 1, 2 Not applicable.
Follow Hizentra: new trials by email Literature Review of Hizentra trials Research Report on Hizentra
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of TAK-664 in People With Primary Immunodeficiency Diseases Who Have Not Yet Been Treated With Immunoglobulins TAK-664 - Primary Immunodeficiency Diseases (PID) | Phase 4 | Not yet recruiting | Takeda | 9 | 2026-11-01 | 2026-09-08 |
| Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies IgPro20 - Secondary Immune Deficiency | Phase 3 | Recruiting | CSL Behring | 63 | 2026-09-15 | 2026-10-14 |
| A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma Gamunex-C, 10% Injectable Solution - Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma | Phase 3 | Recruiting | Grifols Biologicals, LLC | 49 | 2026-05-11 | 2026-10-01 |
| A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Gamunex-C, Xembify - CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) | Phase 3 | Recruiting | Grifols Therapeutics LLC | 40 | 2026-04-02 | 2026-10-09 |
| Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia IgPro20 - Multiple Myeloma, Hypogammaglobulinemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 100 | 2025-05-08 | 2026-10-05 |
| Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS IgPro20, Placebo - Post-COVID Postural Orthostatic Tachycardia Syndrome | Phase 3 | Terminated | CSL Behring | 16 | 2024-08-28 | 2026-04-13 |
| Usage of Spirometry in Managing IgG Therapy in CVID With Airway Disease Hizentra - Common Variable Immunodeficiency | Phase 4 | Recruiting | University of Alabama at Birmingham | 22 | 2024-01-15 | 2026-05-04 |
| IVIG vs SCIG in CIDP Intravenous immune globulin G, Subcutaneous immune globulin G - CIDP, Immunoglobulin Deficiency | Phase 1 | Recruiting | Rutgers, The State University of New Jersey | 20 | 2022-09-11 | 2025-12-11 |
| Immunoglobulin Replacement Therapy for Immunoglobulin G Subclass 2 Deficient Patients With Bronchiectasis Cuvitru 20 % Injectable Solution - Bronchiectasis, Immunoglobulin Subclass Deficiency | Phase 4 | Withdrawn | University of Edinburgh | 2022-08-05 | 2021-09-29 | |
| Hizentra® in Inflammatory Neuropathies - pHeNIx Study Hizentra - Chronic Inflammatory Demyelinating Polyneuropathy | Recruiting | CSL Behring | 100 | 2022-06-10 | 2025-01-07 | |
| Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial) Gamunex-C, Albumin - Immune-Mediated Necrotizing Myopathy | Phase 2 | Withdrawn | University of Washington | 2022-05-01 | 2022-10-24 | |
| Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19) GAMUNEX-C, Standard Medical Treatment - COVID-19 | Phase 2 | Completed | Grifols Therapeutics LLC | 100 | 2020-09-17 | 2022-10-07 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency Gamunex-C, IVIG-PEG - Primary Immunodeficiency | Phase 3 | Completed | Grifols Therapeutics LLC | 33 | 2020-09-02 | 2023-06-05 |
| Subcutaneous Immunoglobulin for Myasthenia Gravis subcutaneous immunoglobulin (SCIG), intravenous immunoglobulin + subcutaneous immunoglobulin (SCIG) - Myasthenia Gravis | Phase 2 | Completed | University Health Network, Toronto | 30 | 2020-08-28 | 2025-04-27 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM) human immunoglobulin G, Placebo - Dermatomyositis | Phase 3 | Terminated | CSL Behring | 134 | 2019-10-21 | 2025-12-09 |
| Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc) IgPro20, IgPro10 - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Completed | CSL Behring | 27 | 2019-09-19 | 2024-02-05 |
| Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig Hizentra - Secondary Immune Deficiency Disorder | Phase 2 / Phase 3 | Completed | Rochester General Hospital | 20 | 2018-11-05 | 2020-08-26 |
| Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN) CUVITRU - Primary Immunodeficiency Diseases (PID) | Completed | Baxalta now part of Shire | 126 | 2018-09-24 | 2021-03-05 | |
| Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig 20% subcutaneous immunoglobulin - Secondary Immune Deficiency | Phase 2 / Phase 3 | Completed | Rochester General Hospital | 16 | 2017-07-21 | 2021-04-19 |
| Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects HYQVIA, KIOVIG, Cuvitru - Primary Immunodeficiency Diseases (PID) | Phase 4 | Completed | Baxalta now part of Shire | 42 | 2017-05-30 | 2023-01-11 |
Showing 20 of 41. Sign in to see all of them.
Primary Immunodeficiency Diseases (14) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (6) · Myasthenia Gravis (4) · Agammaglobulinemia (3) · Common Variable Immunodeficiency (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Multiple Myeloma (3) · Dermatomyositis (2) · Lymphoma, Non-Hodgkin (2) · Agammaglobulinemia, non-Bruton type (1) · Biliary Atresia (1) · Bronchiectasis (1) · Bruton type agammaglobulinemia (1) · Burkitt Lymphoma (1) · COVID-19 (1)
CSL Behring (16) · Grifols Therapeutics LLC (4) · Baxalta now part of Shire (2) · Rochester General Hospital (2) · University of South Florida (2) · Grifols Biologicals, LLC (1) · Mayo Clinic (1) · Mazen Dimachkie, MD (1) · Memorial Sloan Kettering Cancer Center (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Rutgers, The State University of New Jersey (1) · St. Louis University (1) · Takeda (1) · Thomas Jefferson University (1) · University Health Network, Toronto (1)
United States (27) · Canada (11) · France (8) · United Kingdom (8) · Germany (7) · Poland (7) · Italy (6) · Japan (6) · Spain (6) · Czechia (5) · Australia (3) · Belgium (3) · Romania (3) · Sweden (3) · Switzerland (3)
Adam T Hill, MBChB MD (1) · Averell Sherker, MD (1) · Balamurali K Ambati, M.D., Ph.D., M.B.A. (1) · Ed Doo, MD (1) · Elie Haddad, MD (1) · Ghazala Hayat, M.D. (1) · Hans Katzberg, MD (1) · Harry Schroeder, MD/PhD (1) · Jafar Kafaie, M.D. (1) · James S Andrews, MD (1) · John Sleasman, MD (1) · Luigi Brunetti, PhD (1) · Mazen M Dimachkie, MD (1)
PMID 24412910, PMID 20454851, PMID 21553933, PMID 21674136, PMID 21705277, PMID 24504846, PMID 27342758, PMID 27455854, PMID 29122523, PMID 30664564, PMID 33025378, PMID 33409867, PMID 34653210, PMID 35934726, PMID 39289739, PMID 39909490, PMID 42578463
2016 (2), 2018 (2), 2023 (2), 2008 (1), 2015 (1), U01DK062456 (1)